AVXL - NASDAQ: AVXL Investor Notice: Update in Lawsuit for Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) announced by the Shareholders Foundation | Benzinga
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) shares.
Investors, who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) shares prior to February 2022 and continue to hold any of those NASDAQ: AVXL shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On December 2, 2022, Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's ...
AVXL) announced by the Shareholders Foundation>Full story available on Benzinga.com